

SCHOLZ DataBank

ADR Control Panel (ADR CP)

User Manual

Version 1.01 February1st, 2025

Summary of the features of the SCHOLZ Databank ADR CP:

- highly innovative and dynamic drug drug interaction checker
- provides the "all in one" overview of drug risks in a patient medication
- reconciles multiple kinetic interactions and adverse drug effects
- e²CP technology visualizes alerts and makes medication errors transparent at one glance
- multiple e²CP technology: paves the way for the doctor's fast track to find safe polypharmacy prescriptions for multimorbide patients within seconds
- Quattro Optimizer to find safer polypharmacy prescriptions for multimorbide patients
- interface to EMR- and E-prescribing software
- based on prescriber information, literature and FDA interaction guide lines
- RXCUI, NDCCODE and Surescripts approved drug database interface for e-prescribing available
- More than 40 years proven experience in the development of drug interaction checkers

The ADR CP is available on https://adrcp.scholzdatabank.com/

Please ask for your credentials to use the ADR CP and write to support@scholzdatabank.com .



SUM	MARY OF THE FEATURES OF THE SCHOLZ DATABANK ADR CP	1
INTR	RODUCTION TO THE ADR CONTROL PANEL (ADR CP) INCLUDING A PATIENT (CASE3
VITA	AL SIGNS AND MAJOR SERIOUS SIDE EFFECTS ANALYZED	13
OPTI FIND	MIZING MEDICATIONS: THE ADR CP AS THE FAST TRACK IN POLYPHARMA SAFER MEDICATIONS!	CY TO 16
GENI	ERAL RULINGS HOW THE ADR CP WORKS	19
MDD OTHI	I: ASSESSING AT ONE GLANCE HOW ONE DRUG MIGHT BE AFFECTED BY ALL ER DRUGS OF THE MEDICATION	L 22
HOW	THE ADR CP MAY BE INTERFACED TO EMR AND OTHER THIRD PARTY SOFT	FWARE
REFE	ERENCES AND LITERATURE	26
SPEC	CIFIC LITERATURE FOR THE ADR CP INTRODUCTION	27
APPE TO E	ENDIX: TECHNICAL DESCRIPTION OF THE INTERFACE TO CONNECT THE ADI MR OR E-PRESCRIBING SOFTWARE	R CP 28
INTRO	DDUCTION	28
1.	FUNCTIONAL FLOW	28
2. 3.	1.1. Showing the ADR CP screen 1.2. Getting info back from ADRCP screen	28 29
4.	1.3. FLOW DIAGRAM	32
5.	1.4. Additional Screens in SDBClientConnect	32
6.	TECHNICAL FLOW	
6.1	Dатаваse	33



Introduction to the ADR Control Panel (ADR CP) including a Patient Case

The **ADR CP** is the "all in one" representation of adverse drug risks which helps the user to keep the overview over kinetic drug interactions and dynamic adverse drug reactions and thereby take the fast track to drug safety and avoidance of serious medication errors when prescribing. The core of the **ADR CP** consists of a highly innovative and dynamic literature based drug interaction checker which reconciles the control of **MDDI** (Multi-Drug Drug Interactions) and **ADR** (Adverse Drug Risks) in a patient medication. Thereby, the **ADR CP** makes the impact of kinetic and dynamic drug interactions on vital signs and adverse drug risks of major importance transparent and recognizable at one glance.

The following screen presents the empty **ADR CP** before entering drugs of a Medication or transmitting the drugs from an EMR- or E-prescribing software:



ADR CP Version 1.0 provides the following functions in the main screen:



• Account: In the Top Right corner of the screen is the User Account details. User name initials are visible there. Right next to it is a drop-down menu. The User can log out using this option.



User can also turn off/turn on Icon Description using the given option.

• Drugs: may be added (+) or deleted (-)



• The position of the medicine added is dependent on the clicked button position. add (+) and delete (-) buttons are present on the header row right next to Total ADR

Total ADR: ~ 283% A

ADR / Drug: ~ 94%

MDDI



- Add button present in the header row will always add medicine to the bottom of the list.
- Delete button present in the header will remove all the drugs in the current Medication and all other Medications and also reset the optimizer. clicking this button shows the warning message: "This will delete all your drugs & reset the optimizer. Are you sure?". click OK to delete all drugs.
- Add and delete buttons that show on each drug row affect individual rows.
 - Add (+) button add the new drug below the clicked button. When a new drug is added, index numbers are updated. Add button on MULTAQ 400 MG Oral Tablet" added the "Panadol Extra Strength 500 MG Oral Tablet" below it.

SCHOLZ DATABANK

	Total ADR: ~ 22%	ADR / Drug: ~ 7.22%		IDDI						
1	MULTAG	400 MG Oral Tablet 主	$\oplus \bigcirc$							
2	Panadol Extra Strength 500 MG Oral Tablet									
3	simvasta	tin 80 MG Oral Tablet		DI						

- Delete button removes the individual row on which the button (-) is clicked. e.g. clicking on the delete button on the row number 1 will delete it. Warning message: "This will delete the MULTAQ 400 MG ORAL TABLET and recalculate the results. Are you sure?" will be shown for confirmation. Click OK to delete the drug.
- The ADRCP is refreshed on add, delete, or updated operations. New calculations are performed and results are updated according to the new drug list.
- Info tab is present right next to the Operations tab. clicking this button will open up the MDDI Levels guidance.

Operations	Info		HEART 🤎
INTE RELE (DA	RACTION VANCE INGER)	MDDI LEVELS	active and
Total ADR:	~ 22%	ADR / Drug: ~ 7.22%	

• Operations Tab is the default selected tab. It has an Optimizer button and Traffic lights for Drug Interactions (DI) and – not yet active in ADR CP 1.0 - for Contraindications (CI), After Effects (AE), and Drug Allergies (AL).

Traffic lights are clickable buttons that also act as indicators. These have Green, Yellow, and Red Traffic lights. By default No light is visible and the ADR summary panel is empty/blank.





Adding one drug will show values in ADR summary Panel; please note the tilde in front of the % values indicating that all values are approximate assessments. Adding more than one drug will update the ADR summary panel, and turn on the traffic lights according to the



results.

Below the Traffic lights is the ADR summary panel.

• ADR CP shows loaders when a component is loading. One loader is visible at the bottom right corner of the screen. it becomes visible when any component is loading or some calculations are being performed. The second loader appears in the relevant components for example if DI(Traffic light) is loading then you can observe the following screen.



- ADR: with each drug entered the e²CP function (see below) is activated and presents the **ADR CP** with the **MDDI** alerts for the drug drug interactions and the **ADR** warning lights for the adverse reactions related to the drugs. The organ sorted table contains 31 side effects that are related to vital signs or serious potential adverse effects which should be avoided.
- Optimizer: when more than 2 drugs are entered the Optimizer function can be used.
- Literature for relevant drugs/ drugs involved can be viewed using the literature button(icon: a medical book) where available.





• The taskbar at the footer (bottom of the screen) provides access to the introductory user manual and legal information you should know when using the **ADR CP**.

Introduction Legal Terms Privacy Policy Contact Us

Please look at the ADR CP for the fictitious patient Willy Nottingham in screen 1 below:

Willy Nottingham is an elderly multimorbide patient. He suffers from severe cardiac arrhythmia, hypertension, and cholesterolemia. He suffers also from a Major Depressive Disorder (MDD) and in these days from an acute bacterial bronchitis which requires antibiotic treatment. Basically each drug listed might be appropriate to treat a specific disease or condition of Willy Nottingham. But what about the multiple mutual impacts and possible adverse effects? The **ADR CP** of SCHOLZ Databank helps to answer these questions.



The new **e²CP technology** ("electronic express ChromaPictography") provides the **ADR CP** even for complex medications as chromapictogram within seconds. It reminds of running chromatograms in a chemist's lab, however with very high speed and performance.

The special alerts stand for: **DI** = classical drug drug interactions; **MDDI** = multi(ple) drug drug interactions; **Lights in the Table** = warnings for dangerous = ADR-1 adverse effects (colors: red,



red-black) or important = ADR-2 adverse effects (colors: yellow, yellow-black) as sorted by organs. More details are described in the following chapters.

The adverse drug risks focussed on in the **ADR CP** table may be dependent on the magnitude of the (multi) drug drug interactions detected. They are in particular related to the vital signs and serious drug side effects as listed in the **ADR CP** main screen. Size and color of the ADR alerts in the cells visualize the relevance and frequency of the adverse effects.

When clicking on the **DI** or **MDDI** alerts or the **warning lights** in the table **DI**, **MDDI** or **ADR** protocols can be retrieved as a short report.

Clarithromycin is evidently not appropriate to treat the acute bacterial infection in this scenario. Comparing screen 2 (without clarithromycin) and screen 1 (with clarithromycin) shows, that clarithromycin causes especially severe **MDDIs** with dronedarone/Multaq and simvastatin; it has also an important additional impact on aripiprazole, see screens 3, 4, and 5. These impacts mirror also in the big differences of the risk scores displayed such as the Total ADR as well as the ADR-1max and ADR-2max, representing the approximate assessments of especially serious side effects such as Heart Failure or less serious side effects such as Hypotension.







The following screen 3 illustrates the **DI** impact of clarithromycin on the metabolism of dronedarone and the increase of the drug exposure (AUC) to approximately 6.7-fold.

Screen 3	3:											
SDB A	ADR Control Panel ×	+		v –								
$\leftarrow \ \rightarrow$	C adrcp.scholzdata	pank.com		🖻 ★ 🔲 😩 🤼	ctualisieren :							
\delta Neuer	Tab 🚷 Scholz Databank 🔇	SDB GUI 🔇 rest.scholzdatabank 🔇 adrcp.scholzdataba										
Mr. De	emo Patient 🛛 🖉	Diagnoses Name										
	MDDI Protocol of S	cholz Databank for Dronedarone		>	<							
Oper	and possibly known CKI	D stages or pharmacogenetics.			^							
	Parameter	Description	Relative Value	Relative Change								
	F	Bioavailability about	~ 280%	~ 182%	,							
~ 115	AUC	Area under the curve about	~ 670%	~ 570%	82							
extrem high 1 2 3 me	 The (relative) AUC of DRONEDARONE is due to the enzyme inhibition or function impairment assessed to be about ~ 670% of the normal. A dose reduction up to ~ 85% could be indicated (desired Booster-effects exempted). A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed. The Therapeutic Index of DRONEDARONE is low. Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)! Assessments relate to the ingredients declared; relevant active metabolites are assigned to the total active moiety represented by the ingredient, if possible. Any change of dosing has to take place under control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. 											
4	Sources and Liter	ature 💽			۰							
5	Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023											
7				Copyright © by Scholz Databank 2023. All rights reser	ved.							

The following screens 4a and 4b illustrate the dual **MDDI** impact of clarithromycin and dronedarone on the metabolism of simvastatin and the increase of the drug exposure (AUC) to approximately the 12-fold.



	Screen	4a:				
	S SDB	ADR Control Panel 🗙	+			~ – 🗆 ×
	$\leftarrow \rightarrow$	C adrcp.scholzdatab	ank.com		e ★ 🗆	Aktualisieren :
Mich Demo Patient Image: Control of Scholz Databank for Simvastatin MoDI Protocol of Scholz Databank for Simvastatin Image: Control of Scholz Databank for Simvastatin Experimentative of Simvastatin Image: Control of Scholz Databank for Simvastatin Image: Control of Scholz Databank for Simvastatin Image: Control of Scholz Databank for Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin Image: Control of Simvastatin	S Neuer	Tab 🚷 Scholz Databank 🔇	SDB GUI 🔇 rest.scholzdatabank 🔇 adrcp.scholzdataba			
	Mr. D	emo Patient 🛛 🕟	O Diagnoses Name			
MDD1 Protocol of Scholz Databank for Simvastalin Absorption, First Pass Effect And Bioavailability Borwalkability of SiMvASTATN depends on enzyme(syltransporters) CYPSA4, OATP1B1 and P-gp. The impact of inhibitor(s) DRONEDARONE end LARTHROMYCON is shown in the following table: Impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4, OATP1B1 and P-gp. The impact of inhibitor(s) DRONEDARONE end LARTHROMYCON is shown in the following table: Impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4 and or renal function (CKD stage). The impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4 and or renal function (CKD stage). The impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4 and or renal function (CKD stage). The impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4 and or renal function (CKD stage). The impact of information of SiMvASTATN depends on enzyme(syltransporters) Stadat cancer hand Impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4 Mage Stadat cancer hand Impact of information of SiMvASTATN depends on enzyme(syltransporters) CYPSA4 Mage Information Impact of information Mage CYPSA4 Mage Information Impact of information Mage CYPSA4 Mage Information Impact of information Impact of information CYPSA4 Impact of information Information Impact of informat						
Abcrytion, First Pass Effect And Bioavailability Bioavailability of SIMASTATIN depends on enzyme(s) transporte(s) CYP3A4, OATP1B1 and P.g. The impact of inhibito(s) DRONEDBARNE at indicating the impact of the impact o		MDDI Protocol of S	cholz Databank for Simvastatin			×
Absorption, First Pass Effect And Bioavailability Bioavailability SMMASTATIN depends on enzyme(s)/transporter(s) CVP3A4, CATP1B1 and P.g. The impact of inhibitor(s) DRONEDARONE and CARTPHEOMYCIN is shown in the following table: The analysis of the ana	Oper					<u>^</u>
Bioexelability of SIMAS TATIN depend on enzyme(s)/transporter(s) CYP3A4, OATP1B1 end P.gp. The impact of inhibitor(s) BRONEDARONE and ChartmROM/CNIN is shown in the following labie: Tray / Ingredient in the following labie: Tray / Ingred	opoi	Absorption, First F	Pass Effect And Bioavailability			
Outcome and a substrate of the constration of the constrat	DIOC	Bioavailability of SIMVAS	STATIN depends on enzyme(s)/transporter(s) CYP3 hown in the following table:	BA4, OATP1B1 and P-gp. The impact of	inhibitor(s) DRONEDARONE	and
Drug / Ingredient Drug Type CYP3A4 OATP1B1 PfGp SMAXSTATIN Substrate Mager Macer CARTHROMYCIN Blocker Macer Macer RONEDARONE Blocker Macer Macer Metabolism and cellimination Blocker Macer Macer Metabolism and cellimination Blocker Drug Type CYP3A4 Metabolism and cellimination of SIMAVSTATIN depend on enzyme(s) transporter(s) CYP3A4 and/or renal function (CKO stage). The impact of imp	0					
Sint/ASTATIN Subbrails Mager Mager Mager Mager Bin/LASTATIN Biocker Medalum Minor Minor Minor CLARTHROMYCIN Biocker Medalum Minor Minor Minor Pin/Lastabalism and/or relimination of SIM/ASTATIN depend on enzyme(s) transporter(s) CVP3A4 and/or renal function (CKD stage). The impact of imitator(s) CLARTHROMYCIN is shown in the following table: Drug Type CVP3A4 Pin/Lastation Drug Type CVP3A4 More CLARTHROMYCIN Biocker More More Structure Drug Type CVP3A4 More More CLARTHROMYCIN Substratin Complete Structure Co	~ 115	Drug / Ingredient	Drug Type	CYP3A4	OATP1B1 P	/Gp
CLARITHROMYCIN Blocker Meduni Marce Marce RONEDARONE Blocker Blocker Marce Rome Blocker Marce Marce Rome Blocker Marce Marce Marce Rome Blocker Marce Marce Marce Rome Marce Marce Marce Marce Rome Standarder Drug Type CYP3A4 Marce	extrem	SIMVASTATIN	Substrate	Major	Major M	linor
DROMEDARONE Bicker Mygr PROMEDARONE Bicker Mygr Metabolism And Elimination Hematolica elimination of SIMASTATIN depend on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of minination of SIMASTATIN is deploted on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of minination of SIMASTATIN is deploted on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of minination of SIMASTATIN is deploted on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of minination of SIMASTATIN is deploted on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of minination of SIMASTATIN is deploted and the simulation of SIMASTATIN is deploted and the function relation and simulation of SIMASTATIN is deploted and under the curve about - 200% - 400% -	Te	CLARITHROMYCIN	Blocker	Medium	Minor M	linor 🦷 💦
Metabolism And Elimination Metabolism and/or elimination of SIMAASTATIN depend on enzyme(s)/transporte(s) CVP3A4 and/or renal function (CRD stage). The impact of hishibito(s) CLARITHROMYCIN is shown in the following table: <u>bray financiano</u> <u>Dray Type</u> CYP3A4 <u>More and the constraints on CSIMAASTATIN depend on enzyme(s)/transporte(s) CVP3A4 and/or renal function (CRD stage). The impact of hishibito(s) CLARITHROMYCIN is shown in the following table: <u>bray financiano</u> <u>Dray Type</u> <u>CYP3A4</u> <u>More and the constraints on CSIMAASTATIN dependence on CSIMAASTATIN dependence on CSIMAASTATIN CLARITHROMYCIN is shown in the following table: <u>Stat ADE concel baset</u> <u>stat CLARITHROMYCIN is shown in the following table: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence tables: <u>Dependence t</u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u></u>		DRONEDARONE	Blocker		M	lajor 🔛
Image: Status Image: Status<	1	Metabolism And E	limination			
and blor(s) CLARITHROMYCIN is shown in the following table: by gradient by gradient by gradient	2 me	Metabolism and/or elimir	nation of SIMVASTATIN depend on enzyme(s)/trans	sporter(s) CYP3A4 and/or renal function	n (CKD stage). The impact of	
Drug / Ingredient Drug Type CYP3A4 SIM-MASTATIN Substrate Major CLARITHROMYCIN Blocker Ocquite the plant and the substrate and th	3	inhibitor(s) CLARITHRO	MYCIN is shown in the following table:			
Simulation The open of the second billing about Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Simvastatin Image: Simulation of Scholz Databank for Simvastatin Image: Simulation of Simvastatin Image: Simulation of Simvastatin <td< td=""><td>4</td><td>Drug / Ingredient</td><td></td><td>Drug Type</td><td>CYP3A4</td><td></td></td<>	4	Drug / Ingredient		Drug Type	CYP3A4	
Description Blocker CLARTHROMYCIN Blocker Copyright By Schell Catalaces 2023 At apple secreter Steace ab: S	5	SIMVASTATIN		Substrate	Maior	
7 Dot with real with a mean of the prescription of the prescriptin the prescription of the prescription of the prescript	6			Blocker	Medium	
Stream db: • Stok DR Control Reel • • • • • • • • • • • • • • •	7			Diotici	Copyright © by Scholz Databank 2023.	. All rights reserved.
Screen 4b: SDB ADR Control Reel * + C addrepscholzdatabank.com Neuer Te S SDB ADR Control Reel * + C addrepscholzdatabank.com Neuer Te S SDB GUI * retscholzdatabank.com MDDI Protocol of Scholz Databank for Simvastatin MDDI Protocol of Scholz Databank for Simvastatin Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com Addrepscholzdatabank.com A correct and Lifetature Change F Glovenalability about - 550% - 440% Addrepscholzdatabank.com Addrepscholzdatabank.com A correct and Lifetature Change Addrepscholzdatabank. A correct and Lifetature Change Addrepscholzdatabank.com A correct and Lifetature Cifets of SiMVASTATIN is moderate. Pieses note Assessments are usually note under the assumption of linear kinetics (Ifst order kinetics)) Assessments relate to the ingredient of dossing to take place under to cortrol of vial signs and relevant clinical add tabe memory represented by the ingredient, if possible Any change of dosing thas to take place under to cortrol of vial signs and relevant clinical add tabe memory represented by the ingredient, if possible Any change of dosing thas to take place under control of vial signs and relevant clinical add tabe memory represented by the ingredient, if possible Any change of dosing thas to take place under available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Biomation of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 - Crevet 2 due to the metabank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023						• •
SDB ADR.Control Rand SDB ADR.Control Rand X + + C Adrepscholzdatabank.com C Advantationen C C Advantationen C	Screen	4b:				
Image: Control of a drop scholzdatabank.com Image: Autometric of drop scholzdatabank.com Imag	SDB ,	ADR Control Panel 🗙	+			~ - 🗆 X
• New Tek • Solo Classes • New Tek • Solo Classes <td>$\leftarrow \rightarrow$</td> <td>C adrcp.scholzdatab</td> <td>ank.com</td> <td></td> <td>ie ★ 🗆</td> <td>Aktualisieren :</td>	$\leftarrow \rightarrow$	C adrcp.scholzdatab	ank.com		ie ★ 🗆	Aktualisieren :
Mr. Demo Patient Descention MDDI Protocol of Scholz Databank for Simvastatin X and possibly known CKD stages or pharmacogenetics. <u>Parameter Description Relative Value Relative Change F Bioavailability about - 580% - 480% AUC Area under the curve about - 1200% - 1100% The frelative) AUC of SIMVASTATIN is due to the enzyme inhibition or function impairment assessed to be about - 1200% of the normal. A dose reduction up to - 91% could be indicated (desired Booster-effects exempted). The Therapeutic Index of SIMVASTATIN is moderate. Please note: Assessments are usually made under the assumption of linear kinetics) I Assessments relate to the ingredient declared; relevant active metabolites are assigned to the total active more regrared of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature () Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 </u>	S Neuer	Tab 🚷 Scholz Databank 🔇	SDB GUI 🕥 rest.scholzdatabank 🕥 adrcp.scholzdataba			
MDD Protocol of Scholz Databank for Sinvastatin Image: Control of Scholz Databank for Sinvastatin Image: Control of Scholz Databank for Sinvastatin Image: Control of Scholz Databank for Sinvastatin Image: Control of Scholz Databank for Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Sinvastatin Sinvastatin Image: Control of Vital Signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Image: Control of Vital Signs and relevant Clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Image: Control of Vital Signs and relevant Clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitu	Mr. D	emo Patient 🛛 📝	Diagnoses Name			
MDDI Protocol of Scholz Databank for Simvastatin and possibly known CKD stages or pharmacogenetics. Parameter Description Relative Value Relative Change F Aucomation of Subvice Databank for Simvastatin Parameter Description Relative Value Relative Change F Bioavailability about - \$80% - 480% MUD Area under the curve about - 1200% - 1100% Musch Area under the curve about - 1200% - 1100% Musch Area under the curve about - 1200% - 1100% Musch Acces reduction up to ~ 91% - 010.00 m//min is assumed. Musch Anormal renal function/CKD Stage 1 with a renal Clearance of 100.00 m//min is assumed. Musch Anormal renal function/CKD Stage 1 with a renal Clearance of 100.00 m//min is assumed. Musch Net herapeutic Index of SIMVASTATIN is moderate. <						
and possibly known CKD stages or pharmacogenetics. Parameter Description F Bioavailability about ~ 580% ~ 480% AUC Area under the curve about ~ 1200% ~ 110% Minot Accenter of the enzyme inhibition or function impairment assessed to be about ~ 1200% of the normal. A dose reduction up to ~ 91% could be indicated (desired Booster-effects exempted). A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed. Nease note: Assessments relate to the ingredients declared; relevant active metabolites are assigned to the total active moiety represented by the ingredient, if possible. Any change of dosing has to take place under control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature Information of SCHOLZ Databank . the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023		MDDI Protocol of S	choiz Databank for Simvastatin			
Parameter Description Relative Value Relative Change F Bioavailability about ~ 580% ~ 480% AUC Area under the curve about ~ 1200% ~ 1100% More relative) AUC of SIMVASTATIN is due to the enzyme inhibition or function impairment assessed to be about ~ 1200% of the normal. Adse reduction up to ~ 91% could be indicated (desired Booster-effects exempted). A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed. The Therapeutic Index of SIMVASTATIN is moderate. Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)! Assessments relate to the ingredient, if possible. Any change of dosing has to take place under available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Image: Control of Vital signs and relevant Cinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Image: Control of Vital signs and relevant cinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Image: Control of Vital signs and relevant cinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in su	Oper	and possibly known CKE) stages or pharmacogenetics.			▲
Indiraction Description Returne value		Parameter	Description	Relative Value	Relative Change	
AUC Area under the curve about ~1200% ~1100% AUC Area under the curve about ~1200% ~1100% The (relative) AUC of SIMVASTATIN is due to the enzyme inhibition or function impairment assessed to be about ~ 1200% of the normal. A dose reduction up to ~ 91% could be indicated (desired Booster-effects exempted). A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed. Image: Courter of SIMVASTATIN is moderate. Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)] Assessments relate to the ingredient declared; control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Image: Courtes and Literature (2) Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Image: Courtes and Literature (2) Inc., USA, 2023 Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2) Image: Courtes and Literature (2)		E	Biogvailability about	~ 580%	~ 480%	
Acc Area under the curve about 1200x 1100x Image: the curve about 1200x 1200x Image: the curve about 1200x 1200x Image: the curve about 1200x 1200x Image: the curve about 2100x 1200x Image: the curve about 2100x 1200x Image: the curve about 210x 1200x Image: the curve about 210x 1200x Image: the curve about 210x 120x Image: the curve about 210x 120x 120x Image: the curve about 210x 100x 100x Image: the curve about 100x 100x 100x 100x Image: the curve about 100x 100x 100x 100x 100x	0			- 1200%	- 400 %	
 The (relative) AUC of SIMVASTATIN is due to the enzyme inhibition or function impairment assessed to be about ~ 1200% of the normal. A dose reduction up to ~ 91% could be indicated (desired Booster-effects exempted). A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed. The Therapeutic Index of SIMVASTATIN is moderate. Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)! Assessments relate to the ingredients declared; relevant active metabolites are assigned to the total active moiety represented by the ingredient, if possible. Any change of dosing has to take place under control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature 1 Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 	~ 115	AUC	Area under the curve about	120078	110076	11 Bull
A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed. The Therapeutic Index of SIMVASTATIN is moderate. Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)! Assessments relate to the ingredients declared; relevant active metabolites are assigned to the total active moiety represented by the ingredient, if possible. Any change of dosing has to take place under control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature 1 Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz: Databank 2023. All rights reserved.	extrem hiah	The (relative) AUC of SIM	VVASTATIN is due to the enzyme inhibition or funct	tion impairment assessed to be about ~	1200% of the normal.	All
The Therapeutic Index of SIMVASTATIN is moderate. Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)! Assessments relate to the ingredients declared; relevant active metabolites are assigned to the total active moiety represented by the ingredient, if possible. Any change of dosing has to take place under control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz Databank 2023. All rights reserved.	T	A normal renal function/0	CKD Stage 1 with a renal Clearance of 100.00 ml/m	in is assumed.		*
Please note: Assessments are usually made under the assumption of linear kinetics (first order kinetics)! Assessments relate to the ingredients declared; relevant active metabolites are assigned to the total active moiety represented by the ingredient, if possible. Any change of dosing has to take place under control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz Databank 2023. All rights reserved.	1	The Therapeutic Index o	f SIMVASTATIN is moderate.			
 control of vital signs and relevant clinical and lab parameters as well as under regard of the prescriber information and strengths and dosage forms available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz Databank 2023. All rights reserved. 	2	Please note: Assessmen relevant active metabolit	ts are usually made under the assumption of linear es are assigned to the total active mojety represent	kinetics (first order kinetics)! Assessme ted by the ingredient if possible Any ch	ents relate to the ingredients d ange of dosing has to take pla	leclared;
Available. Dose reductions of more than 75% are usually not recommended, and in such cases a substitution of drugs involved is preferred. Sources and Literature Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz Databank 2023. All rights reserved.	3 me	control of vital signs and	relevant clinical and lab parameters as well as und	er regard of the prescriber information a	and strengths and dosage for	ns
 Sources and Literature Information of SCHOLZ Databank - the drug reference tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz Databank 2023. All rights reserved. 	3	available. Dose reduction	ns of more than 75% are usually not recommended	, and in such cases a substitution of dru	igs involved is preferred.	
Information of SCHOLZ Databank - the drug reterence tool for drug information and interactions since 1981 © All rights reserved, SCHOLZ DATABANK Inc., USA, 2023 Copyright © by Scholz Databank 2023. All rights reserved.	4	Sources and Litera				
Copyright © by Scholz Databank 2023. All rights reserved	5	Information of SCHOLZ	Databank - the drug reference tool for drug informa	tion and interactions since 1981 © All rig	gnts reserved, SCHOLZ DATA	ABANK
Copyright © by Scholz Databank 2023. All rights reserved.	6					
	7				Copyright © by Scholz Databank 2023	. All rights reserved.
						•

Page 11 of 34 Confidential Information

© Copyright 2025 by SCHOLZ DATABANK, Inc. - Wilmington and New York, U.S.A. - All international Rights Reserved



The following screen 5 illustrates the dual **MDDI** impact of paroxetine and clarithromycin on the metabolism of aripiprazole at enzymes CYP2D6 and CYP3A4 and the increase of the drug exposure (AUC) to approximately the 4-fold.



n 5:											
B ADR Control Panel 🗙	+				 ✓ - □ 						
C adrcp.scholzdataba	ink.com				• 🖻 ★ 🔲						
er Tab 🚷 Scholz Databank 🔇	SDB GUI 🔇 rest.scholzdatabank 🔇 adro	p.scholzdataba									
Clinic and Labs	Symptoms / Complaints										
MDDI Protocol of So	holz Databank for Arininrazok	-			\sim						
		8			^						
Drug / Ingredient		Drug Type	CYF	P2D6 C1	(P3A4 ^						
ARIPIPRAZOLE		Substrate	Ma	ajor M	edium						
CLARITHROMYCIN		Blocker		M	edium						
DRONEDARONE		Blocker	Mi	inor							
PAROXETINE		Blocker	Ma	ajor							
Assessment Of Ph	armacokinetic Parameters										
The following table gives	a survey over the kinetic parameters	based on the reported	drug interactions, propert	ies of substrate(s) and inhib	pitor(s) given.						
and possibly known CKD	stages or pharmacogenetics.		0 /1 1		()0 /						
Parameter	Description		Relative Value	Relative Cl	hange						
F	Bioavailability abo	ut	~ 100%	~ 0%							
AUC	Area under the curve a	about	~ 400%	~ 300%	%						
The (relative) AUC of ARIPIPRAZOLE is due to the enzyme inhibition or function impairment assessed to be about ~ 400% of the normal. A dose reduction up to ~ 75% could be indicated (desired Booster-effects exempted). A normal renal function/CKD State 1 with a renal Clearance of 100.00 ml/min is assumed											
	5			Copyright © by Scholz Datab	ank 2023. All rights reserved.						
uction Legal Terms Priv	acy Policy Contact Us										

If you want to learn more details about the **MDDI** technology please read the special chapter below:

MDDI: Assessing at one glance how one drug might be affected by ALL other drugs of the medication

Vital Signs and Major Serious Side Effects analyzed

The ADR CP has its focus on the following adverse/side effects:

QT interval prolongation, bradycardia, tachycardia, heart failure, hypertension, hypotension, syncope, respiratory depression, bronchospasm, acute hepatic failure, acute renal failure, seizure, extrapyramidal symptoms, serotonin syndrome, reaction time impaired, anticholinergic burden, severe and moderate bleeding, agranulocytosis, hypoglycemia, hyperglycemia, hypokalemia, hyperkalemia, hypomagnesemia, dizziness, falling risk. Terms in italic writing are usually classified as dangerous adverse effects, represented also by ADR-1 and ADR-1-max values.

Thereby vital signs and major serious side effects may be effectively controlled. The **ADR CP** may be supplemented in the future by additional side effects. As the computation of all multiple drug drug interaction and side effects with their ADRs is very complex limits are only set by the hardware capabilities and high



performance computers (HPC) are needed to process user requests in user friendly response times. This applies in particular when optimizing of medications is the target as described in the next chapter.



In the case of Willy Nottingham the potential clinical results due to the pharmacokinetic and pharmacodynamic interactions can be retrieved in short protocols, for example for dronedarone/Multaq or simvastatin. In particular unacceptably high ADRs for dronedarone and its side effects QT prolongation or Heart Failure and for simvastatin and its side effects acute Liver or Renal Failure make clear that the medication has to be adapted and optimized to avoid severe harm to the patient, see for example screens 6.

Screen 6:																													
SDB ADR Control Panel	× +																								\sim	-	I		×
← → C adrcp.schol	zdatabank.com																					Ê	*) [. (Aktual	sieren	;)
🕄 Neuer Tab 🚷 Scholz Databan	k 🕥 SDB GUI 🌘	rest.schol	zdatabar	ık (3 •	drcp.so	holza	databa	a																				
	Ealt view	Symptom	is / Comj	olaints																									-
Clinic and Labs	QT-prolongatio	on				ADR:	~ 12	2.0%																					J
Operations Info	Drug name	ADR-	Notes			Lear	n More		0	RGA	NS 🛉		ľ	IER	VES			E	BLOO	DD		L	AB R	RESI	JLT	s 🖉			
		class						-1								SUL													
	DRONEDARONE	extremely high	Note: : due to	ide eff increa	ect (sed	Acu	te R	enal	Fail	ure					ADF	R: ~ 0	.329	6	lired	s/s	28 ON	ale	<u>e</u>	a				en.	
ADR-1-max ADR-1-max			6-fold (AUC)	increas throug	ed e h	Dru	g nar	ne		ADR- class	Note	s			Ŀ	arn Mo	•	4	Union in	OF OF	ing M	100 Se.	all contractions	rks. mis	Kal mia	calconia	magnese	ess of	2
extremely extremely very		hiah	CLARI	HKUN	IYCI	SIM	/AST/	ATIN	_	high	Note	: sid	e effec	t enh	ance	d due	to	₽¢	e	B	2 4		24	2 1	2 2	\$ \$	á	E dille	
high high		medium	Note:	ide eff	ecto					2	incre	asec	AUC (of ab	out 1	1-fold			155					V	V	Call	a 88		
600% Drug: ~ 1			due to	increa	sed						DRO	asec NED	i expos ARONI	ure (E and	AUC)	throu	gh		<u>)</u>	ſ	B	ŧŸ	₽Ÿ	Ť	÷	↓ ↓	^y 🔞	î¶	
1 MULTAQ 400 MG Ora	l Tablet	\bigcirc	0								CLAF	атн	ROMY	CIN														•	
2 candesartan cilexetil 16 M	G Oral Tablet			•		CAN	IDESA	ARTAN	1	low								•						•					
3 metoprolol succinate 25 MG Release Oral Cape	24HR Extended MDC		•		0	CLA	RITHF	ROMY	(CIN	low				_	_	_	_	•									0	•	
4 simvastatin 20 MG Ora	al Tablet MD	DI			\square						•		•		Τ	Т		Γ				•					•	•	
5 PARoxetine HCI 25 MG 244 Release Oral Tab	IR Extended let	• •		•	•		•				•	1	•		•		•			•	•						•	•	
6 ARIPiprazole 20 MG Or	al Tablet MDC	•	•		•	•	•				•	(•		0					•					•	•	
7 clarithromycin 500 MG C	Dral Tablet	•	•								•		•	•			٠	•		•			•					•	
Introduction Legal Terms	ntroduction Legal Terms Privacy Policy Contact Us ADR_CP Copyright © by Scholz Databank 2023. All rights reserved.																												

If you want to learn more details about the ADR assessment please read the special chapter below:

General Rulings how the ADR CP works

The ADR CP develops its power, especially in complex polypharmacy scenarios and when treating multimorbide elderly patients. For this purpose, it provides the Quattro Optimizer function, and we shall see in the following chapter how a medication containing dronedarone/Multaq, simvastatin, and clarithromycin can be improved.



Optimizing Medications: The ADR CP as the fast track in polypharmacy to find safer medications!

By using the new technology of providing multiple e²CPs the productivity to find better solutions for complex polypharmacy prescriptions may be tremendously enhanced and improved.

ADR CP 1.0 helps the user to compare up to four different medications and - by substituting drugs causing serious adverse risks – to find alternative medication scenarios with less risk.

When clicking the Optimizer Button the complete medication of the main screen is presented in the Quattro Optimizer screen in Medication 1 but also in Medication 2, Medication 3, and Medication 4.

er	n 7:																													_
	SDB ADR Control Panel ×	+																									-			
	→ C 😋 adrcp.scholzdataba	ink.com																						0	2	Q	z	¥)
tim	nizer of Scholz Databank																													
	Active Medication 1 2 3 4	O	201	XÇ	Ģ	9	ÔC	12	Ċ			3	Ś.	8	2	DQ)41	2	(þ	je (26	6	.ę	. 9	K ŧ	K C	a M	9	0 '	Śŗ.
DR	2 ~ 528% extremely high ADR/drug ~ 106% extremely high	nely high	ADR-	-1	~ 1145	6	extrem	ely hi	igh	ADR-1 max	-	~ 10	0%	ext	treme	ly higi	h 4	ADR-2	~ 4	14%	Ve	ry hig	h	AD m	R-2- iax	~ 1	00%	ve	y high	
T	MULTAQ 400 MG Oral Tablet	D (•	0					T	•		•	Т	Τ				\bigcirc								Т	Т		•	
	simvastatin 40 MG Oral Tablet	MDDI								•		•	•	•	1			•									+	•	•	
t	ARIPIprazole 20 MG Oral Tablet	MDDI	• •	•			•	•	•			•	(•	•	• •	•	\bigcirc											•	
	PARoxetine HCI 20 MG Oral Tablet	•	•			•	•					•	(•	•	•	•	ŏ			•		+				-	0	•	
	clarithromycin 500 MG Oral Tablet									+	-	•	•	•	•	•	-	•	•	-	•	+	•				-		•	
edic	cation 2																													
DR	2 ~ 528% extremely high ADR/drug ~ 106% extremely high	nely high	ADR-	-1	~ 1143	6	extrem	ely hi	igh	ADR-1 max	-	~ 10	0%	ext	treme	ly higi	h A	ADR-2	~4	14%	Ve	ery hig	h	AD m	R-2- nax	~ 1	00%	Vei	ry high	
	MULTAQ 400 MG Oral Tablet	D I (◉	C						•		•						$oldsymbol{O}$											•	
	elmvastatin 40 MG Oral Tablet	MDDI			_					•		•	•	•				•										•	•	
	ARIPIprazole 20 MG Oral Tablet	MDDI	• •	•			•	• •	•			•	(•	\odot	• •	•	$oldsymbol{eta}$										۲	•	
-	PARoxetine HCI 20 MG Oral Tablet		• •			•	•					•	(•	•	•	•	\odot			•									
	clarithromycin 500 MG Oral Tablet			•								•	•	•	•	•		•	•		•		•						•	
DR	cation 3 R ~ 528% extremely high ADR/drug ~ 108% extrem	nely high	ADR-	-1	~ 1145	6	extrem	ely hi	igh	ADR-1 max	-	~ 10	0%	ext	treme	ly higi	h 4	ADR-2	~ 4	14%	Ve	ry hig	h	AD	R-2- nax	~ 1	00%	ve	ry high	
1	MULTAQ 400 MG Oral Tablet		◉	0						•	1	•						$oldsymbol{O}$											•	
-	simvastatin 40 MG Oral Tablet	MDDI								•	1	•	•	•				•										•	•	
3	ARIPIprazole 20 MG Oral Tablet	MDDI	• •	•			•	•	•			•	(0	•	•	0										•	•	
4	PARoxetine HCI 20 MG Oral Tablet	D	• •			•	•	(•	(•	•	•	•	\odot			•							0	•	
5	clarithromycin 500 MG Oral Tablet			•								•	•	•	•	•		•	•		•		•						•	
edic	cation 4																													
ADR	2 ~ 528% extremely high ADR/drug ~ 106% extremely high	nely high	ADR-	-1	~ 1143	6	extrem	ely hi	igh	ADR-1 max	-	~ 10	0%	ext	reme	ly higi	h A	ADR-2	~4	14%	VE	ry hig	h	AD m	R-2- iax	~ 1	00%	vei	y high	
1	MULTAQ 400 MG Oral Tablet	DI (•	0						•		•						$oldsymbol{0}$											•	
2	almvastatin 40 MG Oral Tablet	MDOI								•	(•	•	•				•										•	•	
																								Сору	right C	by Sch	olz Dat	abank 2	D25. All ri) k

Medication 1 remains always as the original medication which shall be optimized. Selected Medication is marked with a check/tick sign. Medication added to Selected Medication also appears automatically in the ADR CP main panel while adding a drug to non-selected Medications is only visible in



Optimizer.

Medication 2, 3, and 4 can be adapted by adding, deleting or substituting the drugs;



they can all at any time send to the main screen by clicking on the matching Check in the header line. Adaptations and substitutions of medications require medical-pharmaceutical expertise of the user; future versions of the ADR CP shall be supported additionally by automated processes to find and compare similar drugs appropriate for the purposes desired.

The simulation of different scenarios is efficiently supported as values for the ADR, ADR/drug, ADR-1, ADR-1-max, ADR-2, and ADR-2-max are updated with each change in a scenario and Medications 1, 2, 3, and 4 can be compared accordingly, see screen 8. Ideally ADR-1-max should be $\leq 0.1\%$ and ADR-2-max $\leq 10\%$.





Substitution by erythromycin reduces the major kinetic **MDDI** interactions caused by clarithromycin, however, as displayed in screen 8 for Medication 2, there is furthermore a substantial increase of the dronedarone induced risk of QT prolongation which should be avoided; therefore cephalexin instead of the macrolides would be the better choice and it does not show any impact on the QT interval as also displayed in screen 8 for Medication 3. Substitution by the alternate cephalosporine cefaclor or the penicillin amoxicillin would yield similarly reduced ADR values.



General Rulings how the ADR CP works

When you enter or delete a drug in the drug listing by clicking the green "+" or "-" button and have selected a special item for the listing the (multiple) drug drug interactions and the ADR over all 31 slanted listed side effects are assessed and the ADR displayed as Total ADR and ADR/Drug in %. As already pointed out: the tilde in front of the % values indicates that all values are approximate assessments.

The ADR (Adverse Drug Risk) for an adverse effect or side effect is the risk in % based on the occurrence and frequency of the side effect and related side effects at normal therapy and dosing of the drug(s) involved. It may have values from 0 to 100% for a single ADR as a function of the relative dose (Doserel: default average value = 0.5 and maximum value = 1) including overdosage due to MDDI kinetics and a defined basic ADR, for example as shown in the diverse following graphs:



The aggregate value over all drugs and side effects in the **ADR CP** (Total ADR) may be higher than 100%; this Total ADR as well as the ADR/ Drug is useful when comparing different medication scenarios with the target to minimize the risk. Single ADRs shall accord to the Prescriber Information for a drug as approved by the FDA in the U.S. or the EMA in Europe or international scientific literature. Frequencies of side effects are most times assigned to classes which refer to the WHO probability classes of side effects: very common/frequent, common/frequent, occasional, rare, very rare (1).



ADR Frequencies and Classes

Side effects may differ from each other by their severity. Taking regard of looking a) at dangerous/serious or b) important side effects ADR %-values are assigned to different ADR classes, see Table 1 and Table 2.

ADR	ADR Class 1	Meaning in numbers	Reference number
Frequency		0	
0	0	means: 0	
Practically ZERO	No risk/light green	>= 0 and < 0,0005% means: 1 - 4 "the basic risk in the population \Leftrightarrow no risk"	Out of 1 million cases/persons
Extremely rare	Very low/light yellow	>= 0,0005% means: 5 - 10	Out of 1 million cases/persons
Very rare	Low/lightest red	>=0,001% means: 11 – 99	Out of 1 million cases/persons
Rare	Medium/light red	>=0,01% means: 100 – 999	Out of 1 million cases/persons
Occasional	High/orange-red/ or red	>=0,1% means: 1,000 – 9,999	Out of 1 million cases/persons
Frequent	Very high/red/ or red-black	>=1% means: 10,000 – 99,999	Out of 1 million cases/persons
Very frequent	Extremely High/black	>=10% means: more than 100,000	Out of 1 million cases/persons

Table 2: n) ADR Frequencies and Classes for important Side Effects (ADR-2)

ADR	ADR Class 2	Meaning in numbers	Reference number
Frequency			
0	0	means: 0	
Practically	No risk/light green	>= 0 and < 0,0005%	Out of 1 million cases/persons
ZERO		means: 1 - 4	
		"the basic risk in the	
		population \Leftrightarrow no risk"	
Extremely	Extremely low/green	>= 0,0005% means: 5 -	Out of 1 million cases/persons
rare		10	
Very rare	Very Low/light yellow	>=0,001% means: 11 –	Out of 1 million cases/persons
		<mark>- 99</mark>	
Rare	Low/yellow	>=0,01% means: 100 –	Out of 1 million cases/persons
		<mark>999</mark>	
Occasional	Medium/light orange	>=0,1% means: 1,000	Out of 1 million cases/persons
		– 9,999	



Frequent	High/orange	>=1% means: 10,000 – 99,999	Out of 1 million cases/persons
Very frequent	Very High/red	>=10% means: more than 100,000	Out of 1 million cases/persons

Higher ADR values are represented by bigger traffic lights than smaller ADR values and by redblack color or orange-black color in the **ADR CP**.

If several drugs in a medication cause the same side effect it is usually assumed that the cumulative effect and the ADR respectively are by a pharmacodynamic drug interaction increased. In particular the literature concerning the QT interval prolongation emphasizes this point (10, 11, 12, 13); this view is in accordance with the established drug policy to declare drug combinations contraindicated, not recommended or usable only with caution, dependent on the magnitude of the proven or potential risk. In the case that the blood concentration of a QT drug is substantially elevated through one or more other drugs (so called pharmacokinetic interaction), a dose dependent risk increase is assumed, in particular if the expected extent of the plasma level rise accords to overdosage (10, 11, 12). In the case that side effects of drugs may favor the precipitation of serious QT prolongations such as hypokalemia, hypomagnesemia, bradycardia, or heart failure (10, 11, 12, 13) additional risk scores may be taken into account following the method of Tisdale (12).

ADR and cumulative Risks

For purposes of assessing cumulative risks mean representative %-values of the ranges of these classes are used such as 20% (very frequent), 5% (frequent), 0.5% (occasional), 0.05% (rare), 0.005% (very rare), as more specific data is frequently not reported. If drug A has a 5%-frequency and drug B has a 5%-frequency of the side effect, the cumulative risk is 10%. Such a cumulative ADR is not necessarily the real side effect risk when drug A and B are used concomitantly, but it represents a rough indicator to judge this risk. Potential synergy effects and their consequences, therefore, have for now to be assumed by the user her- or himself. With higher doses of the drug(s) involved or high MDDI alert level, which signalize overdosing, a relatively higher ADR is assumed as the majority of side effects are represented by type A ("augmented") dose-related effects (14) and nowadays even uncommon type B ("bizarre") immune-mediated effects are increasingly regarded to be to some extent dose-related (15).

The basic formula for a specific ADR_i dependent on the side effect frequencies FREQ_ij and the AUCrel_j due to drug or multiple drug drug interactions of DRUGS_j (with i = 1...n side effects and j = 1...m drugs) is:

ADR_ij = SUM (FREQ_ij * f(AUCrel_j))

Whereby applies in the default case a slightly overproportional ADR/FREQ increase according to the following rule of thumb:



f(AUCrel) = AUCrel²/SQRT(AUCrel)

Risk factors may increase ADRs as multiplyers; such risk factors may exist for example due to age (RAGE), Sex (RSEX), renal stage or GFR (RREN), or pharmacogenetic properties (RPG) as well as risk favoring other side effects (RADR) and a risk potentiation factor RPF to mirror synergy effects. ADR CP Version 1.0 is confined to drug data; therefore only RADR may play a role, for example if drug related hypokalemia favors the occurrence of QT prolongation. Future ADR CP versions with an EMR interface will also process patient individual data.

Please note:

The SCHOLZ Databank ADR Software is according to the FDA policy NOT a Medical Device (16, 17). It enables the health care professional as a user to independently review the basis of the information provided by the specific ADR CP software functions, such that the health care professional does not rely primarily on the information to make a clinical decision about an individual patient; the user of the ADR CP is asked – and this is mandatory - to control any information provided through the ADR CP by her or his professional expertise and checking the up-to-date prescriber information and literature also available through the software. Any use of the ADR CP presumes the acceptance of the End User License agreement by the user.

MDDI: Assessing at one glance how one drug might be affected by ALL other drugs of the medication

MDDI: The new View on Drug Drug Interactions

The **MDDI** drug interaction technology supports a completely new view on drug drug interactions; Niemi et al. reported in 2000 and 2006 the results of two in-vivo-studies where repaglinide and loperamide respectively and their AUC were affected to an unexpectedly high extent through multiple drug drug interactions (2, 3). Based on these findings and contributions from Ohno et al. (3) and Isoherranen et al. (4) a general concept for processing multiple drug drug interactions (**MDDI**) including especially drug absorption and metabolism was developed and incorporated into the SCHOLZ Databank drug interaction software which has been developed since 1980 (6, 7). **The MDDI** tool was helpful to better understand a published case report of rhabdomyolysis caused by the multiple impact of amlodipine and ciprofloxacin on the kinetics of simvastatin (8, 9). Thus it helps the user to recognize immediately, how one drug is kinetically affected by ALL other drugs of the medication. The **MDDI** alerts bring this message to the user; they symbolize the interaction magnitude by different colours from light yellow over red to black according to the relative increased AUC (AUCrel) of the drug affected by the interaction or multiple interactions.

Classical Drug Drug Interactions are usually presented through pairs of interacting drugs. In particular in polypharmacy it occurs frequently, however, that an adverse effect is subject to multiple pharmacodynamic



and/or pharmacokinetic impacts. Then it can become very tedious to puzzle together what might be the outcome when several drugs of a polymedication interact and have a direct or indirect impact on such an adverse effect. The MDDI technology overcomes this problem and makes possible to assess at one glance how one drug might be affected by ALL the other drugs of the medication. Let us look again at the already mentioned fictitious case of the multimorbide patient Willy Nottingham and his ADR CP in screen 12:

Screen 12:																													
SDB ADR Control Panel × +																									~	-	C	כ	×
\leftrightarrow \rightarrow \mathbf{C} $\hat{\mathbf{e}}$ adrcp.scholzdatabank.com	n																							07	Ê	*			:
🔇 Neuer Tab 🚷 Scholz Databank 🔇 SDB GU		rest.sch	olzdata	bank	0	adrcp.s	cholz	databa	а																				
Clinic and Labs		Sympto Age an	oms / C Id Risk I	omplair Factors	nts																								J
Operations Info		HEA	RT (P	CIRC	ULAT	10N	-O	0	RGA	NS	i		NE	RV	ES (0		BLO	OD		LA	B R	ESU	LTS	5 Ø			
	mizer				6		tens:	40,		risis	sion		1 ⁹	lure		Solo Color	SUS	tome of the	irea	2	in the second	ale	ø	~			à	BIII	
ADR-1-max O ADR-2 ~ 115% ~ 100% ~ 481% ~ 10	- max 0%	Sy Carol	Weardia	rolongatic	Olene.	Static L	on, og	erension	ertensive	aton Dopt	to . Ospass	Liver F.	C Renal Fa	4	"Yramidan	- 	ronin Su	Lin Stra	ound on the	A second	ding M.	ding Seve		erkalo II	Otalen ia	ocalcemi	enegnese,	iness.	N.
extremely extremely very high very high high	high ,	20 2	8 6	`* ·	£° (£ \$	- A	, A	498 898	\$	Acc	Acu	40	Et.	ŝ	ર્જ	00	4 ⁰⁰	₽ ⁰ 4	4	" Å	A.	22.2	£ 2	a z	S. Z.S	Ő	alle a	
Total ADR: ~ ADR / 595% Drug: ~ 85%	MDDI),)	P		12	Ċ	ß	99		Ś	K	P		40	4)	2	<u>j</u>	ļo ģ	6	6	, ₽	, P	K €	K C	CaMe	9 👸	Ň	
1 MULTAQ 400 MG Oral Tablet	DI	•	۲	\odot							۲							0										•	1
2 candesartan cilexetil 16 MG Oral Tablet					•						•	•						•	•					•			•		1
3 metoprolol succinate 25 MG 24HR Extended Release Oral Capsule		•		•	(•				•			•					0									0	•	
4 simvastatin 20 MG Oral Tablet	MDDI										۲	۲	٠					•									•		
5 PARoxetine HCI 12.5 MG 24HR Extended Release Oral Tablet		•			•		•				•		•	•	•	•		•		•	•						•	•	
6 ARIPiprazole 15 MG Disintegrating Oral Tablet	MDDI	•	•		(•	•				•		0	0	•	•		•									•	•	
7 clarithromycin 500 MG Oral Tablet		•	•								•	•	•	•	•			•	•	•			•					•	
•																													
Introduction Legal Terms Privacy Policy Contact Us Copyright © by Scholz Databank 2023. All rights reserved.										1.																			

As visible through the MDDI buttons there is for example a major problem for simvastatin. The exposure to simvastatin amounts probably due to diverse inhibitions of transporters and enzymes to more than the 10-fold, which is unacceptable high. The following screen 13 of the MDDI protocol illustrates the scenario:



Screen 13:

Image: Constraint of the set of t	SDB ADR Control Pane	× +							- 0	×
Scholz Data ADD Control Data Q Control Data Control	← C ▲ Nicht sich	er adrcp.scholzdatabank.com					b	⇒ A ^N tõ t	i 🕀 🙎)
Mr. Demo Patient Biodwalability of SIMVASS IATIN depends on enzyme(s) transporter(s) CYP3A4, OATP1B1 and P.gp. The impact of inhibitor(s) DRONEDARONE and CLARITHROMYCIN is shown in the following table: INTERACTION RELEVANCE INTERACTION RELEVANCE INTERACTION RELEVANCE INTERACTION Biocker Metabolism And Elimination Biocker Metabolism and/or elimination of SIMVASTATIN depend on enzyme(s) transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of inhibitor(s) CLARITHROMYCIN is shown in the following table: Total ADR = 320% Drug / Ingredient Integration Substrate American Substrate SimVASTATIN Substrate Inhibitor(s) CLARITHROMYCIN is shown in the following table: Drug / Ingredient SimVASTATIN Substrate Major Inhibitor(s) CLARITHROMYCIN is shown in the following table: Drug / Ingredient SimVASTATIN Substrate Major CLARITHROMYCIN Biocker Medium ARRENDAR Assessment Of Pharmacokinetic Parameters Biocker Medium Anterprint Assessment Of Pharmacokinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pha	With the second state ADD Constrat Density Patient Data MDDI Protocol of Scholz Databank for Simvastatin Ausorption, First Pass Effect and ploavailability								Risk Focus	Q★↓↓
Clinicator Interaction RELEVANCE Conversion Clinicator SimVASTATIN CLARITHROMYCIN Blocker Medium Moor Minor Minor Minor Minor Minor Minor CLARITHROMYCIN Blocker Medium Moor Mediolism And Elimination SimVASTATIN Metabolism and/or elimination of SiMVASTATIN depend on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of inhibitor(s) CLARITHROMYCIN is shown in the following table: Total ADR - 320% Total ADR - 320% Antipiper Antipiper Antipiper Antipiper Antipiper Antipiper Bioker Antipiper CLARITHROMYCIN Biocker Medium SimVASTATIN CLARITHROMYCIN Biocker Medium CLARITHROMYCIN Biocker Moor CLARITHROMYCIN Biocker Medium CLARITHROMYCIN </th <th>Mr. Demo Patient</th> <th>CLARITHROMYCIN is sh</th> <th>own in the following table:</th> <th>ransponer(s) CYP3A4, O</th> <th>ATP1B1 and P-gp. The Impac</th> <th>a of inhibitor(s) DRONED</th> <th>ARONE and</th> <th></th> <th></th> <th>•</th>	Mr. Demo Patient	CLARITHROMYCIN is sh	own in the following table:	ransponer(s) CYP3A4, O	ATP1B1 and P-gp. The Impac	a of inhibitor(s) DRONED	ARONE and			•
Siture action Siture action Siture action Major Minor Interaction CLARITHROMYCIN Blocker Medium Minor M	Clinic and	Drug / Ingredient		Drug Type	CYP3A4	OATP1B1	P/Gp			±ĭ
INTERACTION RELEVANCE (DANGER) RELEVANCE (DANGER) Relabolism And Elimination Metabolism and/or elimination of SIMVASTATIN depend on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of inhibitor(s) CLARITHROMYCIN is shown in the following table: Total ADR - 3205 1 2 3 3 3 4 ARITHROMYCIN Biocker Drug Type CYP3A4 SimVASTATIN CLARITHROMYCIN SimVASTATIN CLARITHROMYCIN Biocker Meduum 1 1 1 2 3 3 4 ARIUPIDER 5 PRR 6 a dictore		SIMVASTATIN		Substrate	Major	Major	Minor			0
RELEVANCE (BANGER) DRONEDARONE Blocker Major Metabolism And Elimination Inhibitor(s) CLARITHROMYCIN is shown in the following table: Metabolism and/or elimination of SIMVASTATIN depend on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of inhibitor(s) CLARITHROMYCIN is shown in the following table: Torug Type CYP3A4 1 Image: Comparison of SIMVASTATIN depend on enzyme(s)/transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of SIMVASTATIN Substrate Major 2 SIMVASTATIN Substrate Major 3 CLARITHROMYCIN Blocker Meduum 4 ARlipipaz Assessment Of Pharmacokinetic Parameters The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Image: Comparison of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics.	INTERACTION	CLARITHROMYCIN		Blocker	Medium		Minor			•
Metabolism And Elimination Netabolism And Flimination Metabolism And Flimination Metabolism and/or elimination of SIMVASTATIN depend on enzyme(s)transporter(s) CYP3A4 and/or renal function (CKD stage). The impact of inhibitor(s) CLARITHROMYCIN is shown in the following table: Total AR = 320% 1 2 3 4 ARRIPIPEZ 5 6 dictored	RELEVANCE (DANGER)	DRONEDARONE		Blocker			Major			
Image: Single and the second secon	Alert size in Total ADR = 320%	Metabolism And El Metabolism and/or elimin inhibitor(s) CLARITHRON	imination ation of SIMVASTATIN depend IYCIN is shown in the following	on enzyme(s)/transporter table:	(s) CYP3A4 and/or renal func	tion (CKD stage). The im	pact of	Min and Caller	Anno of the second	· +
2 3 CLARITHROMYCIN Blocker Medium 4 ARIPIpizz Assessment Of Pharmacokinetic Parameters Image: Clarit diamon di diamon diamon diamon diamon diamon diamon diamon diamon	1	SIMVASTATIN			Substrate	aior				
3 a 4 ARIPIPION 5 PAR 6 dictore	2 si	CLARITHROMYCIN			Blocker	dium		•		
7 clari Parameter Description Relative Value Relative Change	3 4 ARIPipraz 5 PAR 6 diclofe 7 clar	Assessment Of Pha The following table gives and possibly known CKD Parameter	armacokinetic Paramete a survey over the kinetic param stages or pharmacogenetics. Descript	ers heters based on the report	ted drug interactions, properti Relative Value	es of substrate(s) and inf Relative (iibitor(s) given, Change			
F Bioavailability about 580% 480%		F	Bioavailabilit	y about	580%	%			•	
AUC Area under the curve about 1200% 1100%	Contact Us Legal Terms	AUC Privacy Policy	Area under the c	curve about	1200%	1100 Copyrig	1% ht © by Scholz Dat	abank 2023. All r		Ê

The overview gives a transparent representation of substrates and blockers and which transporters and enzymes are involved and affected with the result that the exposure (AUC) of simvastatin is up to about 1200% meaning the 12-fold. More specific insights are available as Absorption and Metabolism chapters are separately shown, but the aggregate conclusion for the increased relative AUC is presented, too.

In scenarios where more than one comedications substantially influence the metabolism of the substrate at very different enzymes the MDDI technology helps the user in particular to keep the survey having much less hassle to puzzle together what the aggregate blocking effect out of these different impacts might be. Please remember the MDDI protocol of aripiprazole in screen 14.



SDB ADR Control Panel + SDB ADR Control Panel + C adrep.scholzdatabank.com Neuer Tab Scholz Databank Stob Z Databank SDB SUI Oper MDDI Protocol of Scholz Databank for Aripiprazole Drug / Ingredient Drug Type CYP2D6 CYP2D6 CYP3A4 ARIPIPRAZOLE Substrate CLARITHROMYCIN Blocker MRONE DARONE PACXETINE Blocker Minor Assessment Of Pharmacokinetic Parameters The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics.	en 14:					
C adrep.scholzdatabank.com Neuer Tab Scholz Databank Scholz Databank SDB GUI Open Suburget Scholzdatabank. MDDI Protocol of Scholz Databank for Aripiprazole Drug / Ingredient Drug Type CYP2D6 CYP3A4 ARIPIPRAZOLE Substrate CLARITHROMYCIN Blocker DRONEDARONE Blocker PAROXETINE Blocker Major Medium The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics.	SDB ADR Control Panel ×	+			v –	
Neuer Tel Stole Databank Stole Databank restscholzdatabank. adrepscholzdatabank. MDDI Protocol of Scholz Databank for Aripiprazole Drug / Ingredient Drug Type CYP2D6 CYP2D6 CYP3A4 ARIPIPRAZOLE Substrate CLARITHROMYCIN Blocker DRONEDARONE Blocker PAROXETINE Blocker Assessment Of Pharmacokinetic Parameters Description Relative Value Relative Value	→ C adrcp.scholzdataban	ık.com			07 🖻 ★	
MDDI Protocol of Scholz Databank for Aripiprazole Drug / Ingredient Drug Type CYP2D6 CYP3A4 ARIPIPRAZOLE Substrate Major Medium CLARITHROMYCIN Blocker Minor Medium DRONEDARONE Blocker Minor Medium ARROXETINE Blocker Major Medium Parameter Description Relative Value Relative Change	Neuer Tab 🚷 Scholz Databank 🔇 S	DB GUI 🔇 rest.scholzdatabank 🔇 adr	cp.scholzdataba			
MDDI Protocol of Scholz Databank for Aripiprazole Drug Type CYP2D6 CYP3A4 ARIPIPRAZOLE Substrate Major Medium CLARITHROMYCIN Blocker Medium DRONEDARONE Blocker Minor PAROXETINE Blocker Major Assessment Of Pharmacokinetic Parameters Blocker Major The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Relative Value Relative Change	Clinic and Labs	Symptoms / Complaints				
Drug / Ingredient Drug Type CYP2D6 CYP3A4 ARIPIPRAZOLE Substrate Major Medium CLARITHROMYCIN Blocker Medium DRONEDARONE Blocker Minor PAROXETINE Blocker Major Assessment Of Pharmacokinetic Parameters Blocker Major The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Relative Value Relative Change	MDDI Protocol of Sch	olz Databank for Aripiprazol	e			×
ARIPIPRAZOLE Substrate Major Medium CLARITHROMYCIN Blocker Medium DRONEDARONE Blocker Minor PAROXETINE Blocker Major Major Assessment Of Pharmacokinetic Parameters The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Relative Value Relative Change	Drug / Ingredient		Drug Type	CYP2D6	CYP3A4	^
CLARITHROMYCIN Blocker Medium DRONEDARONE Blocker Minor PAROXETINE Blocker Major Assessment Of Pharmacokinetic Parameters The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Parameter Description Relative Value Relative Change	ARIPIPRAZOLE		Substrate	Major	Medium	
DRONEDARONE Blocker Minor PAROXETINE Blocker Major Assessment Of Pharmacokinetic Parameters The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Parameter Description Relative Value Relative Change			Blocker		Medium	3
PAROXETINE Blocker Major Assessment Of Pharmacokinetic Parameters Blocker Major The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Relative Value Relative Change	DRONEDARONE		Blocker	Minor		allin
Assessment Of Pharmacokinetic Parameters The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. Parameter Description Relative Value Relative Change	high PAROXETINE		Blocker	Major		Ì
The following table gives a survey over the kinetic parameters based on the reported drug interactions, properties of substrate(s) and inhibitor(s) given, and possibly known CKD stages or pharmacogenetics. me Parameter Description Relative Value Relative Change	Assessment Of Pha	rmacokinetic Parameters				Ĩ,
Parameter Description Relative Value Relative Change	The following table gives a and possibly known CKD s	survey over the kinetic parameters stages or pharmacogenetics.	based on the reported drug	interactions, properties of s	ubstrate(s) and inhibitor(s) given,	
	Parameter	Description		Relative Value	Relative Change	
F Bioavailability about ~ 100% ~ 0%	F F	Bioavailability abo	out	~ 100%	~ 0%	
AUC Area under the curve about ~400% ~300%	AUC	Area under the curve	about	~ 400%	~ 300%	
The (relative) AUC of ARIPIPRAZOLE is due to the enzyme inhibition or function impairment assessed to be about ~ 400% of the normal. A dose reduction up to ~ 75% could be indicated (desired Booster-effects exempted). A normal renal function/CKD Stage 1 with a renal Clearance of 100.00 ml/min is assumed.	The (relative) AUC of ARIF A dose reduction up to ~ 7 A normal renal function/Ck	IPRAZOLE is due to the enzyme in 5% could be indicated (desired Boo (D Stage 1 with a renal Clearance c	hibition or function impairme ster-effects exempted). f 100.00 ml/min is assumed.	ent assessed to be about ~ 4	100% of the normal.	-
Copyright © by Scholz Databank 2023. All rights reserv oduction Legal Terms Privacy Policy Contact Us Copyright © by Scholz Databank 2023. All rights reserv	oduction Legal Terms Priva	acy Policy Contact Us		Copyright ©	Copyright © by Scholz Databank 2023. All rights re by Scholz Databank 2023. All right	served.

The concomitant inhibition of the aripiprazole metabolism through paroxetine/dronedarone at CYP2D6 and clarithromycin at CYP3A4 causes the increase of the AUC up to about 400% or the 4-fold, which is very well in line with what the Abilify prescriber information (18) tells in the chapters about pharmacokinetics and dosing, see the following Table 3:

Table 3: Dose Adjustments for ABILIFY

Dosage adjustment due to drug interactions: Factors

Known CYP2D6 Poor Metabolizers Administer half of usual dose Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors Strong CYP2D6 or CYP3A4 inhibitors Administer half of usual dose Strong CYP2D6 and CYP3A4 inhibitors Administer a quarter of usual dose

Dosage Adjustments for ABILIFY

Administer a quarter of usual dose

As the MDDI technology allows to taper very precisely the properties of the substrates and inhibitors involved, meaning how much a substrate is subject to one or more enzymes/transporters and how much enzymes or transporters might be blocked by an inhibitor, the MDDI assessments of the relative AUC changes accord very well to the results of in-vivo pharmacokinetic studies with deviations of less than 10% in most scenarios reported.

Page 25 of 34 **Confidential Information** © Copyright 2025 by SCHOLZ DATABANK, Inc. - Wilmington and New York, U.S.A. - All international Rights Reserved



How the ADR CP may be interfaced to EMR and other Third Party Software

The ADR CP of SDB is available as a web-based application that can be used online as stand-alone software; SDB ADR CP can also be called through an interface from third party EMR or E-prescribing software and includes the option to submit coded patient data such as drug codes, ICD10-Codes and other patient individual information. Whereas this solution comes with a graphic UI the ADR CP can also be built as a web-based service with UI using the SDB web service based on REST Technology.

For technical details of interfacing please refer to the Appendix of this document: **Technical Description of the Interface to connect the ADR CP to EMR or E-prescribing software.**

References and Literature

SCHOLZ DataBank information is based on up-to-date international prescriber information, literature, and publications of Health Authorities such as the drug drug interaction guidelines of the FDA. Therefore the most recent Prescriber information according to the dailymed web service of the NIH can be retrieved for the drugs entered in the drug listing in the main screen of the **ADR CP** as well as literature related to drug drug interactions and MDDI including direct access to the Medline PUBMED literature service.

SCHOLZ DATABANK

Specific Literature for the ADR CP Introduction

- 1) <u>https://web.archive.org/web/20160304222413/http://www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingc_ourses/definitions.pdf</u>
- Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, p. J. (March 2000). Effects of gemfibrozil, itraconazole, and their combination on the pharma-cokinetics and Pharmacodynamics of repaglinide: potentially hazardous interaction between Gemfibrozil and repaglinide. Diabetologia, S. 347-351.
- Niemi, M., Tornio, A., Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Backmann, J. T. (June 2006). Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol, S. 563-472.
- 4) Ohno, Y., Hisaka, A., Ueno, M., & Suzuki, H. (2008). General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet, S. 47(10):669-80.
- 5) Isoherranen N, Lutz J.D, Chung SP, Hachad H, et al. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol 2012;25:2285–300.
- 6) Wolfgang Scholz: Scholz-Arzneimittel-Datenbank. Deutsche Apotheker Zeitung 1992;132(14):709–12.
- Wolfgang U. Scholz: Zur Pharmakokinetik von Arzneimitteln bei multiplen Interaktionen Theoretische Überlegungen und praktische Umsetzung. Krankenhauspharmazie 2016;37: 497–505.
- 8) Wolfgang Scholz and Stefanie Brune: Arzneimitteltherapie 2016;34 Suppl. 1, S. 2-7
- 9) De Schryver N, Wittebole X, Van den Bergh P, Haufroid V, et al. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine co-administration. Case Rep Nephrol 2015;2015: 761393.
- 10) Matthew Li and Liz G Ramos: Pharmacy and Therapeutics, 2017 Jul; 42(7); 473-477
- Peter J Schwartz and Raymond L Woosley; Journal of the American College of Cardiology, Vol. 67, No. 13, 2016, 1639 -50
- 12) James E Tisdale: Can Pharm J, 2016 May; 149(3): 139-152
- 13) Simko J and I Lörincz, Formatex 2013: 1941 1949
- 14) I R Edwards 1, J K Aronson; Adverse drug reactions: definitions, diagnosis, and management; Lancet 2000 Oct 7;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9.
- 15) Elizabeth J. Phillips; Classifying ADRs does dose matter?; Br J Clin Pharmacol. 2016 Jan; 81(1): 10–12. doi: 10.1111/bcp.12749
- 16) Examples of Software Functions That Are NOT Medical Devices; https://www.fda.gov/medical-devices/device-software-functions-including-mobile-medical-applications/examples-software-functions-are-not-medical-devices
- 17) Policy for Device Software Functions and Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff Document issued on September 28, 2022. <u>https://www.fda.gov/media/80958/download</u>
- 18) Prescriber Information Abilify 06/2018



Appendix: Technical Description of the Interface to Connect the ADR CP to EMR or E-prescribing software

Introduction

The **SDBClientConnect** is a Cloud-based Software

SDBClientConnect will act as a middle layer between EMR and ADR CP software to transfer data.

The data will be transferred in the form of C-CDA (Consolidated Clinical Document Architecture). It's the most widely used format for health information exchange in the US today. Each patient encounter in the healthcare system can be represented by a single document in the Clinical Document Architecture (CDA) style.

SDBClientConnect will take data input from EMR and send it to ADR CP and provide the "all in one" overview of drug risks in a patient medication screen.

1. Functional Flow

2. 1.1. Showing the ADR CP screen

- Keep a centralized database of all EMR customers, their required information, and their assigned license key.
- The cloud EMR delivers the user's information (username, password, API key, and practice code) to **SDBClientConnect** via the POST method. **SDBClientConnect** verifies the user's information and creates a token with security encryption in accordance with OAuth 2.0 Specifications. The **SDBClientConnect** then returns the token if the user is legitimate.
- When the EMR receives the token from the **SDBClientConnect**, it returns the patient's medication details (in CCDA encrypted format) along with the generated token using the POST method.
- Gets the Drugcodes, based on RXCUI's code in Patient medication details
- Using the POST method, the **SDBClientConnect** sends the details (username, password, UCI, and timestamp) to ADRCP. ADRCP validates the details; if it is a valid request, the ADRCP then returns the ADRCPToken to **SDBClientConnect**.

Page 28 of 34 Confidential Information

© Copyright 2025 by SCHOLZ DATABANK, Inc. - Wilmington and New York, U.S.A. - All international Rights Reserved



- Using the POST method, **SDBClientConnect** sends the details (like drug codes and ADRCP tokens) to ADRCP and returns the URL to **SDBClientConnect**.
- The **SDBClientConnect** shows the ADRCP UI in an iframe using the given URL.
- The generated ADRCP UI output is sent back to SDBClientConnect
- **SDBClientConnect** shows the received ADRCP output in Iframe and returns to the EMR

3. 1.2. Getting info back from ADRCP screen

- The **SDBClientConnect** gets a request from EMR with the generated token using the GET method.
- When the **SDBClientConnect** receives the token from the **EMR**, it validates

• Getting Started

- 1. To get started with ADRCP API, please follow these steps:
 - i. Register with Scholzdatabank. please visit the following page to contact us <u>https://scholzdatabank.com/contact-us</u> you can also email us at
 - <u>management@scholzdatabank.com</u> <u>After your registration you will get a registered email & password You can</u>
 - ii. After your registration, you will get a registered email & password. You can use these credentials to make a request to the ADRCP server.
 - iii. Make requests to the appropriate endpoints using the HTTP methods. ADR CP follows the REST API approach.
- **SDBClientConnect** sends an E-mail, Password to ADRCP for Authentication using the **POST** method. The **SDBClientConnect** gets a generated ADRCP Token along with a redirect URL from ADRCP
 - 'POST /api/v1/users/login'
 - Description: authenticate the user and create adrcp_token
 - Parameters: email, password
 - Response: 200 OK with a JSON object containing adrcp_token & a redirect_url.



Page 29 of 34 Confidential Information

© Copyright 2025 by SCHOLZ DATABANK, Inc. - Wilmington and New York, U.S.A. - All international Rights Reserved





- communication through email and password is discouraged. redirect_url_with_adrcp_token can be used to log in.sampleURL
- https://adrcp.scholzdatabank.com/api/v1/users/login?email=useremail@gmail.com&password=user_password
- Using the POST method, **SDBClientConnect** sends the details (like drug codes and ADRCP tokens) to ADRCP and returns the URL to **SDBClientConnect**.
 - 'POST /medicines/adr?medicine_ids='
 - Description: authenticate and add medicines to Medication 1.
 - Parameters: medicine_ids, adrcp_token
 - Response: 200 OK with a html document.
 - Please look in the response header for the response status code.
 - response is a proper HTML document that can be loaded in an iframe. This call also provides a user session and automatically switches user Medication to Medication 1 (that is the default user medication). any medicine added to Medication 1 is also added to Medication 2,3, and 4.
 - <u>https://adrcp.scholzdatabank.com/medicines/adr?medicine_ids=Y13123,Y13944,Y235</u> 36,Y23723&adrcp_token=sPByYnxLrhw8gH9rp_wt (user your own adrcp_token here and medicine_ids are separated by comma)
 - This function provide two functionalities authentication and add medicines so only one call is needed to set up ADR CP in an iframe.
- SDBClientConnect sends ADRCPToken to ADRCP to get the patient's modified medication details to
 SDBClientConnect using GET method
 - 'GET /api/v1/medicines/get_patient_drugs'
 - $\circ~$ Description: Get a list of drugs that the user added in ADRCP in the user current selected medication.
 - Parameters: adrcp_token
 - Response: 200 OK with a JSON array of drug objects.

0	{
	"patdrugs": [
0	{



0	"drug_name": "MULTAQ 400 MG Oral Tablet",	
0	"rxcui": "854859",	
0	"drug_code": "Y25289"	
0	}.	
0	{	
0	"drug_name": "simvastatin 80 MG Oral Tablet",	
0	"rxcui": "200345",	
0	"drug_code": "Y29173"	
0	},	
0	{	
0	"drug_name": "clarithromycin 250 MG Oral Tablet",	
0	"rxcui": "197516",	
0	"drug_code": "Y17224"	
0	}	
0	1	
0	}	

o sample

URL

https://adrcp.scholzdatabank.com/api/v1/medicines/get_patient_drugs?adrcp_token=1rbh tb4rfq_6rxbdqhPH

(please use your own adrcp_token here)

- rxcui is only available for drugs that patient added using the ADRCP. it is not available for the drugs added to ADRCP using the API.
- **SDBClientConnect** converts the patient's medication details into CCDA format and sends it back to EMR



4. 1.3. Flow diagram

Calling ADRCP from EMR through SDBClientConnect



> Getting modified drugs info back from ADRCP to SDBClientConnect



5. 1.4. Additional Screens in SDBClientConnect

• Admin Screens for EMR Client Management: (API Key's and Mapping Practice code & UCI management)



6. Technical Flow

6.1 Database

1. Customer Table

Add fields to ([UserName] [nvarchar](50) NULL,

[Password] [nvarchar](50) NULL

2. AuditLog

CREATE TABLE [dbo].[Audit_Log]([ID] [int] NULL, [CustomerID] [int] NULL, [AccessDate] [DateTime] NULL, [EMRData] [Text] NULL, [Response] [Text] NULL, [SessionID] [nvarchar](500) NULL

) ON [PRIMARY]

3. Session Table

CREATE TABLE [dbo].[SDB_Session]([ID] [int] NULL, [CustomerID] [int] NULL, [SessionID] [Varchar](500) NULL, [AccessDate] [DateTime] NULL

) ON [PRIMARY]

6.2 SDBClientConnect Authentication API from EMR

API : <u>http://localhost/api/auth/Authenticate</u> Type : POST call Input : model { "UserName":"ClientConnect", "Password":"Client1234", "APIKey":"DA-CONNECT-API-KEY-001",

"Timestamp":"{{isoTimestamp}}"

}

Output : Token as String

6.3 Load ADRCP UI From EMR



API: <u>http://localhost/Home/LoadADRCP</u>

Type: POST Call Input : model Header Key : Authorization(Token) { CCDA:"" (Base 64 encrypted string) }

Output : ADRCP UI URL

6.4 Get modified data from ADRCP to EMR through SDBClientConnect

API: <u>http://localhost/Home/GetADRCPModifiedDrugs</u> Type: GET Call Input : model Header Key : Authorization(Token)

Output : updated CCDA

6.5 ADRCP Authentication from SDBClientConnect API : <u>http://localhost/api/auth/ADRCPAuthenticate</u>

Type : POST call Input : model { "e-mailID":"e-mailID",

"Password":"Client1234"}

Output : ADRCPToken and Redirect-URL as String

6.6 Data pullback from ADRCP to SDBClientConnect

Call <Redirect-URL> Type: GET Call Input : model Header Key : Authorization(ADRCPToken) Output : Modified drugs in JSON format The JSON will be converted into CCDA and send back as output to EMR for 2.4 "API: <u>http://localhost/Home/GetADRCPModifiedDrugs</u>"